MedTrace Logo

Refine and Assess the Readability of Patient, Carer, and Clinician Treatment Preference in Myelodysplasia Questionnaire

NCT05817331 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2023-04-18

No results posted yet for this study

Summary

The primary goal of this study is to use qualitative interviews to elicit and confirm concepts related to treatment preferences and understandability of the pTPMQ, cTPMQ, and mTPMQ. The information gathered will be used to support the appropriateness of the questionnaires as a patient-reported, caregiver-reported and clinician-reported outcome measure (PROM) in the population of interest.

Conditions

  • Myelodysplastic Syndrome (MDS)

Interventions

OTHER

Carer Treatment Preference Myelodysplasia Questionnaire

Caregiver-reported outcome measure in MDS

OTHER

Clinician Treatment Preference Myelodysplasia Questionnaire

Clinician-reported outcome measure in MDS

OTHER

Patient Treatment Preference Myelodysplasia Questionnaire

Patient-reported outcome measure (PROM) in MDS

Sponsors & Collaborators

  • Otsuka Australia Pharmaceutical Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Anoop K Enjeti, MBBS FRCP FRCPA PhD · Calvary Mater Newcastle, Edith Street, Waratah, NSW 2298 Australia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-28
Primary Completion
2023-03-10
Completion
2023-03-10

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05817331 on ClinicalTrials.gov